Gland Pharma breakout in one hour time frame
アップデート済
Gland Pharma, founded in 1978 and headquartered in Hyderabad, India, is a pharmaceutical company specializing in injectable formulations. The company focuses on the development, manufacturing, and marketing of high-quality generic injectables, catering to a wide range of therapeutic areas. Gland Pharma is known for its robust product portfolio and strong presence in regulated markets, including the United States, Europe, Canada, and Australia. The company operates under stringent compliance with international regulatory standards, ensuring the delivery of safe and effective products.
Sales Growth:
Gland Pharma has demonstrated consistent sales growth over the past few years. For the fiscal year 2022-2023, the company's revenue was approximately ₹5,303 crore (around USD 660 million). This reflects a steady increase, driven by new product launches, geographical expansion, and increased penetration in existing markets. Strategic partnerships and collaborations have also played a crucial role in enhancing the company's sales performance.
Earnings:
Gland Pharma's earnings have shown significant improvement, supported by its robust sales growth and operational efficiencies. For the fiscal year 2022-2023, the company's net profit was approximately ₹1,397 crore (around USD 174 million). The company has maintained healthy profit margins through cost-effective manufacturing processes and economies of scale. Its focus on high-value products and complex generics has contributed to better pricing power and profitability.
Debt:
As of the latest financial reports, Gland Pharma has maintained a strong balance sheet with minimal debt. The company's debt levels are relatively low, allowing it to leverage its financial position for further growth and expansion without significant financial strain.
THE COMPANY IS EXPECTED TO POST GOOD RESULTS THIS QUARTER ALSO.
Sales Growth:
Gland Pharma has demonstrated consistent sales growth over the past few years. For the fiscal year 2022-2023, the company's revenue was approximately ₹5,303 crore (around USD 660 million). This reflects a steady increase, driven by new product launches, geographical expansion, and increased penetration in existing markets. Strategic partnerships and collaborations have also played a crucial role in enhancing the company's sales performance.
Earnings:
Gland Pharma's earnings have shown significant improvement, supported by its robust sales growth and operational efficiencies. For the fiscal year 2022-2023, the company's net profit was approximately ₹1,397 crore (around USD 174 million). The company has maintained healthy profit margins through cost-effective manufacturing processes and economies of scale. Its focus on high-value products and complex generics has contributed to better pricing power and profitability.
Debt:
As of the latest financial reports, Gland Pharma has maintained a strong balance sheet with minimal debt. The company's debt levels are relatively low, allowing it to leverage its financial position for further growth and expansion without significant financial strain.
THE COMPANY IS EXPECTED TO POST GOOD RESULTS THIS QUARTER ALSO.
トレード稼働中
This stock broke the trend line in one hour time frame and gave a buy signal. Hold with a stop below 1990.Analysed by Ramakrishnan
I am not a SEBI registered analyst.
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。